Delayed pressure urticaria syndrome: a clinical expression of interleukin 1
Open Access
- 1 September 1987
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 67 (5) , 438-441
- https://doi.org/10.2340/0001555567438441
Abstract
Study of a patient with the bullous delayed pressure urticaria syndrome showed remarkable congruence of the extra-cutaneous findings and the known effects of interleukin 1: malaise, fever, myalgia, arthralgia, leukocytosis, increased sedimentation rate, and circulating acute phase reactants. As a result of this "clinical assay" for interleukin 1, we conclude that the delayed pressure urticaria syndrome is the clinical expression of interleukin 1, synthesized in the skin as a result of pressure and released into the circulation. Delayed urticaria, mediated by interleukin 1, is to be contrasted with immediate type urticaria, long known to be histamine mediated.This publication has 9 references indexed in Scilit:
- Interleukin 1 Activity Produced by Human Rheumatoid and Normal Dendritic CellsScandinavian Journal of Immunology, 1986
- Neutrophilic urticariaBritish Journal of Dermatology, 1985
- Clinical, pharmacological and immunological aspects of delayed pressure urticariaBritish Journal of Dermatology, 1984
- Langerhans Cell Production of Interleukin-1Journal of Investigative Dermatology, 1984
- Late cutaneous reactions in patients with delayed pressure urticariaJournal of Allergy and Clinical Immunology, 1984
- Effect of ultraviolet radiation on production of epidermal cell thymocyte-activating factor/interleukin 1 in vivo and in vitro.Proceedings of the National Academy of Sciences, 1984
- Increased thymocyte-activating factor in human gingival fluid during gingival inflammationInfection and Immunity, 1982
- Delayed pressure urticariaJournal of Allergy and Clinical Immunology, 1982
- DELAYED AND PERSISTENT DERMOGRAPHIAArchives of Dermatology, 1950